Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Sutro Biopharma, Inc.NASDAQ: STRO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$38.5M, compared with -$75.97M a year earlier. Trailing-twelve-month income before tax was -$153.72M.

Context

  • Income before tax amounted to 186.5% of revenue in FY2025, down 176.3 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$38.5M or moves back toward the trailing-twelve-month quarterly average of -$38.43M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$38.5M+17.8% QoQ
Last fiscal yearDec 2025
-$191.18M+15.1% YoY
LTMMar 2026
-$153.72M+36.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.3%——
1 year+15.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(191.18M) USD
Year-over-year change
+15.1%

Income Before Tax vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.7% is the 3rd highest of 9, against a peer median of -9.7%.
  • Income before tax amounts to 154.3% of revenue for STRO, versus a peer median of 45683.5%.
STRO Competitors
Income Before Tax for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026-€42.81M EUR+1.7%—145945.5%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.1M USD+38.9%——
DTILPrecision BioSciences, Inc.LTM Mar 2026-$44.49M USD-102.3%—98.7%
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
CNTBConnect Biopharma Holdings LimitedFY2025-$55.28M USD-258.9%—86379.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$87.07M USD-34.3%——
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$108M USD-21.2%——
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$113.22M USD+48.4%——
STROSutro Biopharma, Inc.LTM Mar 2026-$153.72M USD+36.7%—154.3%
Peer median (excluding STRO) —-9.7%—45683.5%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.